Chris Spivey

In this episode of Drug Digest, Pharmaceutical Technology editors discuss the advantages and savings that continuous manufacturing may offer as well as the very real obstacles that might make a fully continuous process not feasible, especially in biologics manufacturing.

Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.

Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.

Lives are saved when time from vein to vein decreases.

Nicole Lewis, PVP Program Manager at Boston Children's Hospital, discusses the science behind precision vaccines, a form of personalized vaccines.

Marcel Baumann, business development director at Recipharm, discusses soft mist inhaler technology from the show floor at the World Vaccine Conference.

What can we take away from Pfizer's acquisition of Seagen?

Decreasing vein to vein time saves lives.

Variability instills consistency in advanced therapy medicinal products.

This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.

This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.

Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”

mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.

Content is king in publishing, but interpretation is imperator.

One can only learn the secrets of "fight club" by attending its meetings.

More than anything else MonkeyPox and COVID-19 have shown that we are interdependent, no matter what continent you call home.

Promising applications for targeted delivery may be cresting the horizon.

As we reach further afield in the molecular universe, we encounter new types of problems to resolve.

Lions and tigers and monkeypox, oh my!

Demand for outsourced services of technical R&D activities is increasing.

FDA is incentivizing drug manufacturers through higher data integrity requirements.

Fresh insight is instrumental in the discussion of novel analytics.

Researchers from the Telomere-to-Telomere Consortium have discovered new properties about junk DNA that could have wide-reaching implications.

3D cell cultures could provide key avenues to unlocking critical information.

Borrowing is good, but invention is best.

The process of reshaping inevitably leads to fresh insights.

Warp speed is amazoning pharma practices and protocols.

We have broken rules, invented new ones, and engineered stronger institutions and supply chains that will serve us better going forward.

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.